Free Trial
→ Many investors are about to lose everything (From Porter & Company) (Ad)tc pixel
NASDAQ:VRCA

Verrica Pharmaceuticals Q3 2026 Earnings Date & Estimates

Verrica Pharmaceuticals logo
$3.60 +0.01 (+0.25%)
As of 10:41 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Verrica Pharmaceuticals is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Verrica Pharmaceuticals in Q3 2026

Verrica Pharmaceuticals is expected to post earnings of -$0.4974 per share on revenue of $6.20 million. In the same quarter a year earlier Verrica Pharmaceuticals reported $0.13 per share on revenue of $14.34 million. Verrica Pharmaceuticals last reported on May 12, 2026, posting -$0.41 per share and beating the -$0.59 consensus estimate. Verrica Pharmaceuticals has beaten the consensus EPS estimate in 6 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.4974
Expected Revenue
$6.20 million
Prior-Year EPS
$0.13
Prior-Year Revenue
$14.34 million
Expected EPS Growth
-482.6%
Expected Revenue Growth
-56.8%

Recent Track Record

Last Reported
Q1 2026
Last Quarter EPS
-$0.41 (Beat by +$0.18)
Last Quarter Revenue
$5.02 million
EPS Beat Rate
6 of last 8 quarters

Prepare for the Q3 2026 Call

Verrica Pharmaceuticals Q3 2026 Earnings FAQ

Verrica Pharmaceuticals (NASDAQ:VRCA) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Verrica Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Verrica Pharmaceuticals to post earnings of -$0.4974 per share for Q3 2026.

The consensus revenue estimate for Verrica Pharmaceuticals is $6.20 million for Q3 2026.

Verrica Pharmaceuticals Earnings Headlines

Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Wall Street Zen to "Strong Sell"
November 7 at 3:22 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31183343
Verrica Pharmaceuticals (VRCA) Set to Post Quarterly Earnings on Friday
November 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31181225
Inside Nevada's 60 Million Ounce Gold Corridor
Barrick Mining has spent decades building one of the world's great gold districts in Nevada, anchored by Fourmile, Goldrush, and Cortez Hills, a region that could hold as much as 60 million ounces of gold. Bordering Fourmile and less than a mile from Goldrush sits a little-known explorer now moving from historical data toward active exploration, setting targets and preparing for a maiden drilling program. With gold trading near record highs, this could be a pivotal stage for an overlooked name in the district.tc pixel
November 10 at 1:00 AM  |  Wall Street Logic (Ad)
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
November 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/11/05/3396383/0/en/verrica-pharmaceuticals-to-report-third-quarter-2026-financial-results-and-provide-a-corporate-update-on-november-12-2026.html
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
October 22, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/22/3386265/0/en/verrica-pharmaceuticals-announces-achievement-of-milestones-unlocking-access-to-the-full-27-5-million-of-non-dilutive-growth-capital-under-credit-facility.html
Lake Street Keeps Their Buy Rating on Verrica Pharmaceuticals (VRCA)
October 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/VRCA-Q/pressreleases/4906010/lake-street-keeps-their-buy-rating-on-verrica-pharmaceuticals-vrca/
See More Verrica Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Verrica Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verrica Pharmaceuticals and other key companies, straight to your email.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals (NASDAQ:VRCA) is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals.

Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older. The product is applied in a healthcare setting and is intended to help treat the viral skin lesions associated with the condition.

The company has also pursued additional dermatology indications for its cantharidin-based product candidate, including common warts, as well as other investigational treatments for skin diseases. Verrica was founded in 2018 and is headquartered in West Chester, Pennsylvania. Its commercial operations have primarily focused on the United States, where YCANTHE is marketed through dermatology and healthcare channels.

View Verrica Pharmaceuticals Profile
Earnings Tools